Skip to main content

Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome.

International journal of cancer

Authors: Deepak B Vangala, Swetlana Ladigan-Badura, Christoph Engel, Robert Hüneburg, Claudia Perne, Karolin Bucksch, Jacob Nattermann, Verena Steinke-Lange, Nils Rahner, Jürgen Weitz, Matthias Kloor, Judith Tomann, Ali Canbay, Huu-Phuc Nguyen, Christian Strassburg, Gabriele Möslein, Monika Morak, Elke Holinski-Feder, Reinhard Büttner, Stefan Aretz, Markus Löffler, Wolff Schmiegel, Christian Pox, Karsten Schulmann

Small bowel cancer (SBC) is the malignancy with the highest standardized incidence ratio in Lynch syndrome (LS) patients. Of all SBCs, about 50% are duodenal cancers (DCs), therefore being accessible by esophago-gastro-duodenoscopy (EGD) for surveillance. We asked whether early detection of DC is possible for LS patients undergoing surveillance by EGD and if surveillance should be limited to specific subgroups. Data for LS patients with DC were retrieved from the registry of the German Consortium for Familial Intestinal Cancer. Patients undergoing active surveillance by EGDs (surveillance group) were compared to those who did not (nonsurveillance group) regarding tumor stage at diagnosis. Union for International Cancer Control stages I-IIA were defined as early stage disease and IIB-IV as advanced stage disease. Statistical analysis was performed using Fisher's exact test. Among 2015 patients with pathogenic variants in any mismatch-repair-gene, 47 patients with 49 DCs were identified. In 10% of cases, patients were under 35 years at diagnosis; family and personal tumor history did not correlate with DC diagnosis. Pathogenic germline variants in MSH6, PMS2 or EPCAM were present in 10% of patients. Statistical analysis could be performed on 13 DC patients in the surveillance group and 14 in the nonsurveillance group. Early detection was possible for 71% of patients in the surveillance group and 29% of patients in the nonsurveillance group (P = .021). Early detection of DC by EGD in LS patients is feasible regardless of family history, mutational status and should start no later than 25 years of age.

© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PMID: 34331771

Participating cluster members